Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
NCT05871970
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
38
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphatic Malformation
Interventions
BIOLOGICAL:
TARA-002
Sponsor
Protara Therapeutics